Basic Ursofalk Information

• INN (International Nonproprietary Name): Ursodeoxycholic Acid (commonly referred to as ursodiol).
• Brand Names Available In United Kingdom: not specified.
• ATC Code: A05AA02 – Ursodeoxycholic acid.
• Forms & Dosages: Capsules 300 mg; Tablets 250 mg and 500 mg.
• Manufacturers In United Kingdom: not specified.
• Registration Status In United Kingdom: not specified.
• OTC / Rx Classification: Prescription-only (Rx) in all major markets.

Latest Research Highlights (UK & EU)

What do the newest studies show about ursofalk and ursodeoxycholic acid?

Recent UK and EU cohort analyses and meta-analyses from 2022–2024 continue to support ursodeoxycholic acid (UDCA, also called ursodiol) as disease‑modifying for primary biliary cholangitis when given at guideline dosing.

Those studies report consistent improvements in alkaline phosphatase (ALP) and better transplant‑free survival among patients treated with recommended doses of 13–15 mg/kg/day.

Randomised data and pooled analyses for gallstone dissolution reaffirm benefit mainly for non‑calcified cholesterol stones.

Clinical trials indicate that long courses of therapy — typically six to 24 months — are required to see stone dissolution, and overall dissolution rates are modest and variable by stone size and composition.

High‑quality randomised controlled trials show limited benefit for mixed or pigment stones, with little effect on calcified stones.

Safety signals in MHRA and EMA pharmacovigilance datasets are predominantly mild gastrointestinal events such as diarrhoea and nausea.

Serious adverse reactions are rare in the reported datasets, with very few confirmed severe allergic reactions.

Formulation and dosing vary across markets, with common strengths including 250 mg and 500 mg tablets and 300 mg capsules.

The drug is indexed under ATC A05AA02 and is used both as Ursofalk in some countries and under generic ursodeoxycholic acid or ursodiol labels elsewhere.

Clinical Effectiveness In The United Kingdom

How effective is UDCA for patients in NHS practice and what do patients report?

UK audit data and reports from regional NHS trusts show that UDCA is the standard first‑line therapy for primary biliary cholangitis in secondary care clinics.

Approximately 40–60% of patients achieve a biochemical response within six to 12 months, commonly measured as a fall in alkaline phosphatase.

Patients often report improvement in pruritus, while relief of fatigue is more variable and may take longer or require additional support.

For gallstones, NHS surgical pathways favour cholecystectomy where clinically appropriate, and UDCA is used selectively for patients who are unfit for surgery or have small, cholesterol‑rich, non‑calcified stones.

Imaging‑confirmed dissolution rates for gallstones vary widely depending on stone composition and duration of therapy.

EU safety registries corroborate low rates of serious adverse events in routine practice.

Community pharmacists and NHS 111 provide common first‑line advice, with NHS clinics offering shared decision making and monitoring.

The usual patient experience is to expect counselling about timelines and monitoring, and to receive clear instructions on liver function tests and follow‑up imaging.

Indications And Expanded Uses

What is licensed and where do clinicians use UDCA off‑label?

Regulatory approvals from EMA and MHRA align with EU practice and list UDCA as licensed for dissolution of certain cholesterol gallstones and for long‑term therapy in cholestatic liver disease such as primary biliary cholangitis.

Standard dosages from product information are roughly 8–10 mg/kg/day for gallstone dissolution and 13–15 mg/kg/day for PBC, with divided dosing.

Emerging UK and EU literature from 2022–24 documents selective off‑label use in specialist centres for conditions such as obstetric cholestasis and some neonatal cholestasis presentations, but the evidence is mixed and specialist oversight is required.

Off‑label prescribing in NHS practice is typically managed by hepatology or gastroenterology teams with documented informed consent and closer monitoring.

Patients expect a clear explanation of what is licensed and what is off‑label, and an explanation of evidence strength and monitoring plans.

• MHRA‑Approved Indications: Dissolving suitable non‑calcified cholesterol gallstones; long‑term therapy in cholestatic liver disease such as primary biliary cholangitis.
• Common Off‑Label Uses: Selected use in obstetric cholestasis and neonatal cholestasis in specialist centres (evidence mixed; specialist review needed).
• Evidence Strength: High for PBC disease modification and biochemical improvement; moderate for gallstone dissolution in selected cholesterol stones; limited for off‑label obstetric/neonatal uses.

Composition And Brand Landscape

What is in the tablet or capsule and which manufacturers supply it?

The active ingredient is ursodeoxycholic acid, also known as ursodiol, classified under ATC A05AA02.

Common dosage forms sold internationally include 300 mg capsules and 250 mg or 500 mg tablets.

Manufacturers and suppliers vary by market and include companies such as Pierre Fabre, Teva and Sandoz across EU markets, while Actigall and Urso labels appear in North American markets.

Packaging varies between blister strips and bottles depending on the manufacturer and country of supply.

In the UK, pharmacies and patients commonly search by brand name such as Ursofalk or by the INN, ursodeoxycholic acid.

Most community pharmacies dispense generic supplies under NHS prescriptions unless a specific brand is clinically indicated.

• Forms And Strengths: Capsules 300 mg; Tablets 250 mg and 500 mg.
• Likely Suppliers: EU suppliers include Pierre Fabre, Teva and Sandoz; brand availability in the UK is not specified in available data.
• INN Vs Brand: INN (International Nonproprietary Name) refers to ursodeoxycholic acid; brand names (for example Ursofalk in some markets) are trade names supplied by manufacturers.

Contraindications And Special Precautions

Who should not take ursodeoxycholic acid and what everyday cautions matter?

Absolute contraindications per product information include complete biliary obstruction and known hypersensitivity to the active substance or any excipient.

Chronic calcified gallstones are an absolute contraindication for the purpose of dissolution because the drug is ineffective against calcified or pigment stones.

Advanced decompensated cirrhosis is a relative contraindication and requires specialist review before use.

Pregnancy and breastfeeding are areas for careful consideration, and clinicians balance risks and benefits on an individual basis.

MHRA safety data reiterate that gastrointestinal events such as diarrhoea and nausea are the most commonly reported adverse effects.

Older patients and those with multiple conditions should be monitored closely, and dose adjustments are dictated by liver function rather than routine renal dosing changes.

Dosage Guidelines

How should dosing be managed in NHS‑aligned care?

Recommended dosing follows weight‑based regimens.

For gallstone dissolution the typical range is approximately 8–10 mg/kg/day, with common adult regimens such as 300 mg twice daily in practice for some patients.

For primary biliary cholangitis the guideline range is 13–15 mg/kg/day given in divided doses, with specialist teams choosing exact dosing and formulation.

Treatment duration differs: six to 24 months for gallstones with periodic imaging to assess dissolution, and long‑term, often indefinite, therapy for PBC with regular liver function monitoring.

Missed dose advice is to take the dose as soon as remembered unless it is close to the next scheduled dose, and to avoid doubling up.

Overdose usually causes mild gastrointestinal symptoms and is treated supportively.

Interactions Overview

Which medicines and foods change how UDCA works?

Major pharmacological interactions are uncommon, but bile acid sequestrants such as cholestyramine or colestipol can reduce absorption if given at the same time.

Antacids and certain other resins may also interfere with absorption and should be separated by a few hours where possible.

Alcohol does not directly interact with UDCA but increases overall liver risk in people with cholestatic disease and should be avoided or limited according to clinician advice.

MHRA Yellow Card reports emphasise gastrointestinal events as the most frequent adverse reports and note rare hypersensitivity reactions.

• Key Interaction: Separate dosing from cholestyramine or similar agents by several hours.
• Key Interaction: Review all medications in elderly patients to check for polypharmacy risks.

Cultural Perceptions And Patient Habits

Where do patients look for information and whom do they trust?

Surveys from 2020–24 show many UK patients first consult online forums such as Patient.info or discussion groups before contacting NHS services for liver or gallstone symptoms.

Trust in community pharmacists and in NHS advice is high, and adherence improves when pharmacists reinforce GP or hospital clinic counselling.

Patients prefer plain‑English explanations, printed or digital leaflets accessible via NHS portals, and clear monitoring plans.

Electronic prescribing and NHS app messaging have increased follow‑up satisfaction and allow pharmacists to support medication queries more effectively.

• Common Belief: Many patients expect symptom relief within months for PBC and understand gallstone dissolution takes much longer.
• Trusted Channels: NHS clinics, community pharmacies (Boots, LloydsPharmacy), NHS 111 and specialist hepatology teams.

Availability And Pricing Patterns

How is ursodeoxycholic acid accessed and what does it cost across the UK?

UDCA is a prescription‑only medicine under MHRA and EMA frameworks, and it is supplied through community pharmacies and hospital pharmacies.

Major pharmacy chains and online pharmacies in the UK stock ursodeoxycholic acid, with electronic prescriptions commonly sent to community dispensing points.

NHS prescribing typically dispenses generics unless a specific brand is clinically required.

Prescription costs vary by UK nation: prescriptions are generally free in Scotland, Wales and Northern Ireland, while England uses a per‑item charge unless patients are exempt or hold a prepayment certificate.

Private prices vary across high‑street and online pharmacies and depend on pack size and brand.

In our online pharmacy, ursofalk is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.

Comparable Medicines And Preferences

What other medicines do clinicians consider for similar problems?

Chenodeoxycholic acid (chenodiol) is an alternative used for gallstone dissolution in some regions but carries a higher risk of hepatotoxicity and therefore is less favoured in many UK settings.

For primary biliary cholangitis, obeticholic acid is an option where UDCA response is inadequate and is typically used in specialist secondary care due to cost and specialist monitoring requirements.

Bile acid sequestrants and other symptomatic treatments are used to manage pruritus but do not have disease‑modifying effects for PBC like UDCA.

Frequently Asked Questions

How long before I see benefits from ursodeoxycholic acid?

For primary biliary cholangitis biochemical improvement is often seen within months, typically in the first six to 12 months of treatment.

For gallstone dissolution patients should expect a long course, usually six to 24 months, with interval imaging to confirm whether stones are dissolving.

Can I drink alcohol while taking UDCA?

Alcohol increases overall liver risk in cholestatic conditions and is discouraged; discuss sensible limits or abstinence with your clinician depending on your liver function.

Is UDCA safe in pregnancy?

Use in pregnancy is cautious and assessed case‑by‑case; some specialist centres use UDCA for obstetric cholestasis under supervision, but you should seek specialist advice before starting or continuing treatment during pregnancy.

How do I obtain ursodeoxycholic acid?

The medicine is prescription‑only and is normally obtained via a GP or hospital specialist and dispensed at community pharmacies or through electronic prescription services.

Useful Links:

For NHS guidance and local hepatology clinic contacts use the NHS website and local specialist trust pages.

Guidelines For Proper Use

What should pharmacists and clinicians cover when counselling patients?

Best‑practice guidance asks for baseline liver function tests and weight‑based dosing, with interval monitoring of LFTs for PBC and imaging for gallstone therapy.

Pharmacists should emphasise adherence, realistic timelines for symptom change, and common side effects such as diarrhoea or nausea.

Patients should be told when to seek urgent care, for example for jaundice, severe abdominal pain or signs of hypersensitivity.

Adverse events should be reported via the MHRA Yellow Card scheme.

• Top‑Line Counselling Points: Explain expected timelines, dosing schedule, missed dose advice and the need for blood tests and possibly ultrasound.
• Escalation Triggers: New jaundice, worsening abdominal pain, sudden severe diarrhoea or rash.

Delivery Across United Kingdom